Table 1. Summary of conditions used for human dermal fibroblast reprogramming.
| Conditions | Protocol 1 | Protocol 2 | Protocol 3 | Protocol 4 |
|---|---|---|---|---|
| Feeder | No | No | Yes | Yes |
| Supplements | No | No | LIF | LIF + Vitamin C |
| Minimum Period of Treatment | 5 days | 5 days | 3 days | 3 days |
| Concentration | 1 μM each | 4 μM each | 0.5 μM each | 0.5 μM each |
| Efficiency | 0.01% | 0.025% | 0.02% | 0.34% |
| CP-RFs | Group A (OSKMN) | Group B (OSKML) | ||
Treatment protocols utilized CP-RF (Group A: OCT4, SOX4, KLF4, CMYC and NANOG; OSKMN) or codon-optimized CP-RF (Group B: OCT4, SOX4, KLF4, CMYC and LIN28; OSKML). Reprogramming efficiencies were calculated as the percent of HDFs giving rise to alkaline phosphatase positive colonies.